ATNX News and Press, Athenex Inc. From 09/10/20

Shares of Athenex (NASDAQ: ATNX) were down by 14.3% as of 1:35 p.m. EDT on Thursday, following the company's announcement of the pricing of a public offering of common stock. With Athenex set to dilute existing shareholders, it isn't surprising that investors are selling off shares of the bi...

Turquoise Hill Resources (NYSE: TRQ ) -21%  after announcing an update on funding discussions with Rio Tinto. More news on: Turquoise Hill Resources Ltd., Precipio, Inc., Muscle Maker, Inc., Stocks on the move, , Read more ...

Athenex (NASDAQ: ATNX ) has priced its public offering of 10M shares at $11.00/share. More news on: Athenex, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

BUFFALO, N.Y., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 sha...

BUFFALO, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to mark...

Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting Company to host conference call and webcast today at 10:30 a.m. Eastern Time SAN FRANCISCO and BUFFALO, N.Y., Sept. 08, 2020 (GLO...

Shares of Athenex (NASDAQ: ATNX) are up by 7.5% as of 12:43 p.m. EDT on Tuesday, after rising by as much as 20.4% earlier today. The market is reacting to Athenex announcing that the FDA has accepted its New Drug Application (NDA) for oral paclitaxel and encequidar for the treatment of metas...

Eastman Kodak (NYSE: KODK ) +44%  on D.E.Shaw stake . More news on: Eastman Kodak Company, Priority Technology Holdings, Inc., Zoom Video Communications, Inc., Stocks on the move, , Read more ...

Under Priority Review status, the FDA has accepted Athenex's (NASDAQ: ATNX ) marketing application seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast cancer. More news on: Athenex, Inc., Healthcare stocks news, Stocks on the move...

FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting BUFFALO, N.Y., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company...